Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 16 | 2019 | 666 | 2.940 |
Why?
|
| Autophagy | 13 | 2018 | 53 | 2.840 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2018 | 89 | 2.460 |
Why?
|
| Heat-Shock Proteins | 5 | 2016 | 28 | 2.440 |
Why?
|
| Estrogen Receptor Modulators | 6 | 2017 | 23 | 2.060 |
Why?
|
| Unfolded Protein Response | 7 | 2017 | 13 | 1.170 |
Why?
|
| Drug Discovery | 2 | 2015 | 30 | 1.070 |
Why?
|
| Apoptosis | 9 | 2018 | 337 | 0.980 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 15 | 0.840 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 546 | 0.830 |
Why?
|
| Tamoxifen | 3 | 2017 | 48 | 0.780 |
Why?
|
| Diet, Mediterranean | 1 | 2018 | 23 | 0.660 |
Why?
|
| Estrogen Antagonists | 3 | 2014 | 14 | 0.650 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 50 | 0.610 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 158 | 0.600 |
Why?
|
| Estradiol | 2 | 2014 | 118 | 0.590 |
Why?
|
| Animals | 20 | 2019 | 7297 | 0.580 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 100 | 0.550 |
Why?
|
| Breast | 1 | 2015 | 53 | 0.520 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 89 | 0.520 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 9 | 0.500 |
Why?
|
| Mice | 10 | 2018 | 2368 | 0.450 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 19 | 0.440 |
Why?
|
| Female | 20 | 2019 | 18164 | 0.440 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2017 | 25 | 0.440 |
Why?
|
| Signal Transduction | 6 | 2015 | 666 | 0.420 |
Why?
|
| Humans | 22 | 2019 | 29093 | 0.390 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 9 | 0.390 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 28 | 0.380 |
Why?
|
| Neoplasms | 1 | 2015 | 610 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 158 | 0.340 |
Why?
|
| Angiotensin I | 1 | 2010 | 262 | 0.330 |
Why?
|
| Blotting, Western | 3 | 2014 | 281 | 0.320 |
Why?
|
| Mice, Nude | 3 | 2014 | 276 | 0.320 |
Why?
|
| Peptide Fragments | 2 | 2011 | 422 | 0.320 |
Why?
|
| Mammary Glands, Animal | 2 | 2019 | 46 | 0.310 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 339 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 680 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 35 | 0.270 |
Why?
|
| Cell Proliferation | 4 | 2018 | 573 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 113 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 46 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 160 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 747 | 0.180 |
Why?
|
| Leptin | 1 | 2019 | 66 | 0.170 |
Why?
|
| Haplorhini | 1 | 2018 | 64 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2018 | 51 | 0.160 |
Why?
|
| Colistin | 1 | 2017 | 1 | 0.150 |
Why?
|
| Soy Foods | 1 | 2017 | 5 | 0.150 |
Why?
|
| Genistein | 1 | 2017 | 14 | 0.150 |
Why?
|
| Phytoestrogens | 1 | 2017 | 16 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 38 | 0.150 |
Why?
|
| Ethinyl Estradiol | 1 | 2016 | 6 | 0.150 |
Why?
|
| Models, Theoretical | 2 | 2015 | 126 | 0.140 |
Why?
|
| Metabolomics | 1 | 2016 | 45 | 0.140 |
Why?
|
| Mitochondria | 1 | 2018 | 174 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2016 | 64 | 0.140 |
Why?
|
| Social Isolation | 1 | 2016 | 42 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2016 | 92 | 0.140 |
Why?
|
| Biological Assay | 1 | 2016 | 16 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 88 | 0.140 |
Why?
|
| Rats | 3 | 2017 | 1604 | 0.130 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Glutamine | 1 | 2014 | 6 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 28 | 0.130 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 62 | 0.120 |
Why?
|
| Aromatase Inhibitors | 1 | 2014 | 7 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2014 | 225 | 0.120 |
Why?
|
| Premenopause | 1 | 2014 | 38 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2014 | 171 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 337 | 0.120 |
Why?
|
| Ovary | 1 | 2014 | 54 | 0.120 |
Why?
|
| Glucose | 1 | 2014 | 163 | 0.120 |
Why?
|
| Estrogens | 1 | 2014 | 162 | 0.120 |
Why?
|
| Cathepsin D | 1 | 2013 | 1 | 0.110 |
Why?
|
| Cathepsin L | 1 | 2013 | 1 | 0.110 |
Why?
|
| Burns | 1 | 2014 | 97 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 401 | 0.110 |
Why?
|
| Wound Healing | 1 | 2014 | 182 | 0.110 |
Why?
|
| Macrophages | 1 | 2014 | 188 | 0.110 |
Why?
|
| Pyrroles | 1 | 2013 | 55 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2014 | 223 | 0.110 |
Why?
|
| Skin | 1 | 2014 | 203 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2014 | 436 | 0.100 |
Why?
|
| Carcinoma | 1 | 2012 | 87 | 0.100 |
Why?
|
| Angiotensins | 1 | 2011 | 49 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 44 | 0.100 |
Why?
|
| Fibronectins | 1 | 2010 | 34 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 82 | 0.100 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 29 | 0.100 |
Why?
|
| Models, Biological | 1 | 2012 | 373 | 0.090 |
Why?
|
| Fibrosis | 1 | 2010 | 102 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 66 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 182 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 384 | 0.080 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2017 | 3 | 0.070 |
Why?
|
| Cell Lineage | 2 | 2015 | 67 | 0.060 |
Why?
|
| Diet | 2 | 2017 | 354 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 33 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 711 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2015 | 256 | 0.050 |
Why?
|
| Obesity | 2 | 2019 | 1063 | 0.050 |
Why?
|
| Adipokines | 1 | 2019 | 15 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 45 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 7 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 33 | 0.040 |
Why?
|
| Thiazoles | 1 | 2018 | 32 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2019 | 138 | 0.040 |
Why?
|
| Pyridines | 1 | 2018 | 78 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 189 | 0.040 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 9 | 0.040 |
Why?
|
| Chickens | 1 | 2017 | 40 | 0.040 |
Why?
|
| Plasmids | 1 | 2017 | 48 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 31 | 0.040 |
Why?
|
| Cattle | 1 | 2017 | 100 | 0.040 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2016 | 5 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2016 | 5 | 0.040 |
Why?
|
| Hydralazine | 1 | 2016 | 8 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2016 | 6 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2016 | 14 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 16 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2016 | 22 | 0.040 |
Why?
|
| Isoflavones | 1 | 2017 | 65 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2017 | 82 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 58 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2016 | 49 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2016 | 47 | 0.040 |
Why?
|
| Swine | 1 | 2017 | 201 | 0.040 |
Why?
|
| Recurrence | 1 | 2017 | 235 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 90 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 327 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 249 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 865 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 249 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 243 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 332 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 980 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 207 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 208 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 11 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 69 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 183 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 272 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 815 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 163 | 0.030 |
Why?
|
| Phagosomes | 1 | 2013 | 4 | 0.030 |
Why?
|
| Lysosomes | 1 | 2013 | 10 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 33 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 217 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 65 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 121 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 519 | 0.030 |
Why?
|
| Risk Factors | 1 | 2016 | 3531 | 0.020 |
Why?
|
| United States | 1 | 2017 | 3630 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3099 | 0.020 |
Why?
|